Company Supported Sessions
Chair(s)
- Ronnachai Kongsakon, Thailand
Session Description
REXULTI: a New Option for Oral Treatment in Schizophrenia - Supported by Otsuka Pharmaceutical Co., Ltd.
Session description
What are your key principles of pharmacotherapy for Schizophrenia? We have many treatment options for Schizophrenia but “unmet needs” still exist. In this “Meet the Expert Session” presented by Otsuka, Dr. Toba from Canada discusses the importance of sustained remission and relapse prevention in optimizing quality of life and patient functioning. Also, he explains the difference between the newest oral antipsychotic, Brexpiprazole (REXULTI), and other existing options based on pharmacological profile.
REXULTI: a New Option for Oral Treatment in Schizophrenia (ID 3747)
Session Type
Company Supported Sessions
Date
09.03.2021, Tuesday
Session Time
10:00 - 11:00
Room
Meet the Expert
Lecture Time
10:00 - 10:00
Session_Icon
Supported by Otsuka Pharmaceutical Co., Ltd. (ID 3806)
Session Type
Company Supported Sessions
Date
09.03.2021, Tuesday
Session Time
10:00 - 11:00
Room
Meet the Expert
Lecture Time
10:00 - 10:00
Session_Icon
Introduction (ID 3807)
Session Type
Company Supported Sessions
Date
09.03.2021, Tuesday
Session Time
10:00 - 11:00
Room
Meet the Expert
Lecture Time
10:00 - 10:05
Presenter
- Ronnachai Kongsakon, Thailand
Session_Icon
REXULTI: a New Option for Oral Treatment in Schizophrenia (ID 3808)
Session Type
Company Supported Sessions
Date
09.03.2021, Tuesday
Session Time
10:00 - 11:00
Room
Meet the Expert
Lecture Time
10:05 - 10:45
Presenter
- Oloruntoba J. Oluboka, Canada
Session_Icon
Discussion and Q&A (ID 3809)
Session Type
Company Supported Sessions
Date
09.03.2021, Tuesday
Session Time
10:00 - 11:00
Room
Meet the Expert
Lecture Time
10:45 - 11:00
Presenter
- Ronnachai Kongsakon, Thailand
- Oloruntoba J. Oluboka, Canada
Session_Icon